晚期卵巢癌患者PARP抑制剂维持治疗期间疲劳体验的定性研究
该定性研究通过半结构化访谈23例接受PARP抑制剂维持治疗且报告中度至重度疲劳的晚期卵巢癌女性,探讨其疲劳体验。主题分析得出四个主题:疲劳较静脉化疗轻但持续限制日常活动;疲劳对自我认同产生负面影响;多数患者因担心复发或死亡而希望继续治疗;患者支持网络对其正在接受癌症治疗及疲劳不知情。研究强调需针对治疗相关疲劳进行干预。
要点
- PARP抑制剂相关疲劳虽较化疗轻,但仍持续限制工作与社交活动
- 疲劳影响患者自我认同,且支持网络常不知情导致孤立
- 患者多因恐惧复发或死亡而倾向继续治疗,需关注疲劳管理
核心结论
- 接受PARP抑制剂维持治疗的晚期卵巢癌患者普遍经历持续性疲劳,疲劳影响多个功能领域,且患者社交网络对口服维持治疗副作用缺乏理解。
- 研究强调需要针对治疗相关疲劳的干预措施,以减轻疲劳对卵巢癌患者福祉的负面影响。
研究设计与样本
- 定性研究,对23例接受PARP抑制剂治疗晚期卵巢癌且报告中度至重度疲劳的女性进行个体半结构化访谈。
- 访谈录音转录后采用主题分析法编码并提炼 emergent themes。
主要发现
- 参与者描述疲劳较静脉化疗时轻,但持续限制日常活动,包括工作和参与家庭社交活动。
- 疲劳对参与者的自我感和身份认同产生负面影响。
- 多数参与者希望继续治疗,认为停用PARP抑制剂会导致癌症复发或死亡。
- 许多参与者报告支持网络不知晓其正在接受癌症治疗或由此产生的疲劳,可能导致孤立和社交支持减少。
临床怎么用
- 临床应主动评估和识别PARP抑制剂维持治疗患者的疲劳,并考虑干预以减轻其对日常功能和生活质量的影响。
- 应关注患者因恐惧复发而坚持治疗的心理,提供充分信息和支持,并帮助患者与支持网络沟通治疗副作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Oral PARP inhibitors (PARPi) have dramatically changed the treatment landscape for patients with advanced ovarian cancer. However, a subset of patients discontinue PARPi due to treatment-related fatigue. The current study sought to explore patients' lived experiences with fatigue on PARPi. METHODS: We conducted individual semi-structured interviews with N = 23 women receiving PARPi for advanced ovarian cancer who reported moderate to severe fatigue. Audiotaped interviews were transcribed and we used thematic analysis to code transcripts for emergent themes. RESULTS: Four overarching themes emerged. First, participants described their fatigue as milder than what they experienced on intravenous chemotherapy, but noted it consistently limited their daily activities, including work, and interfered with participation in family and social events. Second, fatigue negatively impacted participants' sense of self and identity. Third, most wanted to continue treatment and believed discontinuing PARPi would lead to a cancer recurrence or death. Finally, many participants reported that their support networks were unaware of their ongoing cancer treatment or the resulting fatigue; a situation that may prove isolating and result in reduced social support. CONCLUSIONS: Our findings underscore patients' persistent experience of fatigue on PARPi, the impact of fatigue on multiple domains of functioning, and a lack of understanding of side effects resulting from oral maintenance treatments among patients' social networks. Our findings highlight the need for interventions to address treatment-related fatigue to limit the negative impacts of fatigue on ovarian cancer patients' well-being.
引用
- Poort H, Fenton ATHR, Thompson E, et al. Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study. Gynecol Oncol. 2020. PMID: 33190931. doi:10.1016/j.ygyno.2020.10.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。